🔍 Novartis AG has agreed to acquire Calypso Biotech BV, a specialist in immunology, in a deal worth $425 million.
🩺 The acquisition will give Novartis full commercialization rights to CALY-002, an antibody that blocks interleukin-15 (IL-15).
💊 Novartis plans to explore CALY-002 for a range of autoimmune indications with high unmet medical need.
🔬 CALY-002 is currently being evaluated in a Phase Ib trial for celiac disease and eosinophilic esophagitis.
🩺 The acquisition will give Novartis full commercialization rights to CALY-002, an antibody that blocks interleukin-15 (IL-15).
💊 Novartis plans to explore CALY-002 for a range of autoimmune indications with high unmet medical need.
🔬 CALY-002 is currently being evaluated in a Phase Ib trial for celiac disease and eosinophilic esophagitis.
📢 Novartis Acquires Immunology Specialist Calypso Biotech in $425M Deal
Introduction:
Novartis AG has announced its plans to acquire Calypso Biotech BV, a specialist in immunology. Calypso Biotech is known for its antibody, CALY-002, which blocks interleukin-15 (IL-15) and has potential application in various autoimmune diseases.
Main points:
- Novartis AG will pay $250 million upfront to acquire Calypso Biotech BV, along with additional milestone payments
- The acquisition would give Novartis full commercialization rights to CALY-002, an antibody that blocks IL-15
- IL-15 plays a key role in immune function and is involved in many chronic autoimmune diseases
- Novartis plans to explore the potential of CALY-002 across a wide range of autoimmune indications with high unmet medical need
- CALY-002 is currently in Phase Ib trial for the treatment of celiac disease and eosinophilic esophagitis
Conclusion:
The acquisition of Calypso Biotech by Novartis AG provides an opportunity for the development and commercialization of CALY-002, an antibody that blocks IL-15 and has potential applications in multiple autoimmune diseases. This acquisition reflects Novartis’ commitment to expanding its portfolio in the field of immunology and addressing unmet medical needs in autoimmune diseases.
